간신증후군 치료 시장 : 제품 유형, 투여 경로, 환자 중증도, 치료법, 약제 클래스별, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Hepatorenal Syndrome Treatment Market is projected to grow by USD 8.47 billion at a CAGR of 7.45% by 2032.

Hepatorenal syndrome treatment is becoming a high-priority focus within advanced liver disease care because HRS-AKI is a life-threatening form of functional kidney failure that occurs in patients with cirrhosis, ascites, and severe circulatory dysfunction. Current clinical practice centers on rapid diagnosis, withdrawal of nephrotoxic agents and diuretics when appropriate, albumin-supported volume expansion, infection control, vasoconstrictor therapy, and timely liver transplant evaluation.

The market is shaped by the need to improve survival, reverse acute kidney injury, reduce intensive care utilization, and bridge eligible patients to liver transplantation. Terlipressin plus albumin has strengthened the evidence base for pharmacologic management, while norepinephrine and midodrine with octreotide remain important alternatives depending on regulatory availability, care setting, and patient risk profile. Demand is also influenced by the growing burden of alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, viral hepatitis complications, and decompensated cirrhosis worldwide.

Transformative Shifts in the HRS Treatment Landscape

The hepatology and critical care landscape is shifting from delayed rescue treatment toward earlier recognition of HRS-AKI using standardized criteria, multidisciplinary care pathways, and integrated liver-kidney assessment. The International Club of Ascites classification has helped move clinical terminology away from older type 1 and type 2 HRS language toward HRS-AKI and non-AKI phenotypes, supporting more consistent diagnosis and trial design.

Therapeutic change is being driven by wider clinical use of vasoconstrictor therapy with albumin, the U.S. Food and Drug Administration approval of terlipressin for adults with HRS involving rapid reduction in kidney function, and increasing awareness of respiratory failure risk requiring careful patient selection and oxygenation monitoring. Hospitals are also reassessing where treatment should occur, as norepinephrine often requires intensive monitoring while terlipressin may enable protocolized use in specialized liver units when safety criteria are met.

Another major shift is the emphasis on transplant-centered decision-making. Because liver transplantation remains the definitive treatment for many eligible patients with HRS, payers, transplant centers, and hospital networks are aligning HRS protocols with early referral, MELD-based risk stratification, renal replacement therapy planning, and post-transplant kidney outcome monitoring.

Cumulative Impact of Artificial Intelligence on HRS Care

Artificial intelligence is beginning to influence hepatorenal syndrome treatment through predictive analytics, clinical decision support, and operational optimization rather than replacing physician judgment. AI models trained on electronic health records can help identify patients with cirrhosis who are at elevated risk for AKI, infection, sepsis, gastrointestinal bleeding, or progression toward HRS, enabling earlier intervention with albumin, antimicrobial stewardship, and medication review.

In research and clinical development, AI can improve cohort identification for HRS trials, detect eligibility criteria more efficiently, and support real-world evidence generation across transplant centers and tertiary hospitals. Natural language processing can extract ascites status, creatinine trends, vasoconstrictor exposure, albumin use, renal replacement therapy, and transplant outcomes from unstructured clinical notes, creating more reliable longitudinal datasets.

The cumulative impact of AI will depend on rigorous validation, explainability, bias monitoring, and compliance with health data privacy requirements. HRS patients are medically complex and often underrepresented in datasets, so AI tools must be evaluated against clinical outcomes such as verified HRS reversal, need for renal replacement therapy, respiratory complications, waitlist mortality, and transplant-free survival.

Key Regional Insights Across HRS Treatment Markets

North America remains a leading region for hepatorenal syndrome treatment because of advanced transplant infrastructure, high adoption of evidence-based hepatology protocols, and regulatory clarity following the United States approval of terlipressin. The region benefits from specialized liver centers, intensive care capacity, and strong clinical research networks, although access differences persist across rural communities, uninsured populations, Indigenous communities, and patients with alcohol-associated liver disease.

Europe has a mature treatment environment supported by established hepatology societies, public reimbursement systems, and long-standing clinical experience with terlipressin in several markets. European practice is strongly influenced by EASL guidance, transplant prioritization systems, and hospital-based management of decompensated cirrhosis. The European Union adds scale for harmonized regulatory oversight and pharmacovigilance, while the United Kingdom, Germany, France, Italy, and Spain remain important demand centers for protocolized HRS-AKI care.

Asia-Pacific is expanding as cirrhosis care improves across Japan, China, India, South Korea, Australia, and ASEAN markets. Regional momentum is supported by large patient populations, rising metabolic dysfunction-associated steatotic liver disease, persistent viral hepatitis sequelae, and investment in tertiary hospitals, but constrained by variable transplant access, uneven specialist density, and affordability barriers. Latin America, led by Brazil and Mexico, shows growing need due to decompensated cirrhosis prevalence and improving specialty care, while reimbursement, albumin access, dialysis capacity, and transplant availability remain uneven.

The Middle East is gaining momentum through GCC investments in tertiary care, transplant programs, digital health infrastructure, and hospital modernization, particularly in high-income Gulf states. Africa has substantial unmet need, with care often limited by late presentation, constrained access to albumin, vasoconstrictors, dialysis, and transplant services, and high competing burdens from viral hepatitis, alcohol-related disease, schistosomiasis in selected settings, and infection-associated decompensation.

Key Group Insights for Strategic HRS Market Planning

ASEAN markets are becoming more relevant as specialist hepatology services expand in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Demand is linked to viral hepatitis sequelae, alcohol-related liver disease, and increasing metabolic liver disease, while adoption of advanced HRS treatment depends on hospital tier, reimbursement, albumin availability, and access to transplant referral pathways.

The GCC represents a high-investment healthcare cluster where tertiary hospitals, digital health infrastructure, and transplant capabilities are advancing. Greater protocol standardization across Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman can improve early HRS recognition, albumin stewardship, safe vasoconstrictor use, critical care coordination, and continuity between local hospitals and transplant centers.

The European Union provides a structured environment for regulatory oversight, pharmacovigilance, and guideline-driven cirrhosis care, supporting consistent clinical pathways across member states despite national reimbursement variation. BRICS countries represent a large-volume opportunity, with China, India, Brazil, Russia, and South Africa collectively carrying significant liver disease burden and requiring scalable, cost-conscious HRS care models that can operate across tertiary hospitals and resource-constrained public systems.

G7 markets are characterized by strong research capacity, advanced hospital systems, transplant expertise, and higher adoption of novel therapeutics, making them influential in clinical evidence generation and post-approval safety monitoring. NATO countries overlap substantially with North American and European advanced care systems, where military and civilian medical networks may support critical care readiness, supply continuity, cross-border research collaboration, and resilient access to essential therapies during system disruptions.

Key Country Insights in Hepatorenal Syndrome Treatment

The United States is the most commercially visible HRS treatment market due to approved terlipressin availability, high use of transplant-center protocols, intensive care resources, and substantial clinical research activity. Canada emphasizes evidence-based specialty care within provincial reimbursement frameworks, while Mexico faces a growing cirrhosis burden and uneven access to transplant and advanced inpatient therapies. Brazil is the largest Latin American market, with strong tertiary hospitals in major urban centers but regional disparities in hepatology, dialysis, albumin, and transplant access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are important HRS treatment markets because of established hepatology expertise, public health systems, and transplant networks. Germany and France offer advanced hospital infrastructure and clinical research depth, while Italy and Spain have significant cirrhosis care experience and transplant activity. The United Kingdom's liver services support guideline-driven care and transplant referral pathways, although hospital capacity pressures can affect complex inpatient management. Russia has sizable unmet need, with adoption shaped by hospital capacity, procurement, specialist availability, and regional differences in access to advanced liver care.

China and India represent high-volume Asia-Pacific opportunities as large populations, expanding hospital infrastructure, persistent viral hepatitis sequelae, alcohol-related liver disease, and rising metabolic liver disease increase demand for decompensated cirrhosis management. Japan and South Korea have sophisticated specialty care systems, strong diagnostics, and advanced hospital capabilities, supporting protocolized HRS management and careful safety monitoring. Australia combines high-quality hepatology care with transplant expertise, though geographic dispersion can affect timely access for remote and Indigenous populations.

Actionable Recommendations for HRS Industry Leaders

Industry leaders should prioritize evidence-based positioning around clinically meaningful outcomes, including HRS reversal, transplant bridging, avoidance or delay of renal replacement therapy, hospital length of stay, survival, and safety monitoring. Commercial and clinical strategies should reflect that HRS treatment decisions are made by hepatologists, intensivists, nephrologists, transplant teams, pharmacists, nurses, and hospital formulary committees.

Manufacturers and healthcare organizations should invest in education that improves early diagnosis, appropriate albumin use, vasoconstrictor selection, respiratory risk assessment, renal replacement therapy planning, and escalation to transplant evaluation. Real-world evidence programs can strengthen confidence by tracking patient selection, dosing patterns, treatment response, adverse events, oxygenation status, recurrence, and outcomes across diverse hospital settings.

Market access strategies should be region-specific. In advanced markets, the emphasis should be on value demonstration, formulary pathway integration, and pharmacovigilance, while emerging markets require affordability solutions, supply reliability, specialist training, and partnerships with liver centers. Digital tools, including validated AI-based risk alerts, should be implemented cautiously with clinician oversight, transparent governance, and measurable quality-improvement endpoints.

Research Methodology for the HRS Treatment Analysis

This executive summary is based on a structured research methodology combining verified secondary research, clinical guideline review, regulatory analysis, and market triangulation. Core evidence sources include peer-reviewed hepatology and nephrology literature, AASLD and EASL guidance, International Club of Ascites criteria, United States prescribing information, clinical trial registries, transplant organization data, and public health sources such as WHO, OECD, and national health agencies.

The analysis evaluates treatment pathways, regulatory availability, clinical adoption drivers, reimbursement dynamics, regional healthcare capacity, and country-level differences in transplant access. Insights are validated by comparing multiple independent sources and prioritizing data tied to clinical outcomes, regulatory decisions, guideline recommendations, and published evidence rather than speculative market claims.

Where quantitative market estimates are not publicly verifiable, the summary avoids unsupported figures and focuses on evidence-backed directional trends. This approach supports relevance while maintaining the level of accuracy expected by healthcare stakeholders, investors, manufacturers, providers, and policy decision-makers.

Conclusion: The Future of Hepatorenal Syndrome Treatment

The hepatorenal syndrome treatment market is entering a more evidence-driven phase as standardized HRS-AKI diagnosis, vasoconstrictor therapy with albumin, transplant-centered care, and real-world safety monitoring become central to clinical practice. The approval and adoption of terlipressin have increased focus on treatment protocols, patient selection, respiratory risk management, and post-treatment monitoring, while alternative vasoconstrictor strategies remain important across varied health systems.

Future progress will depend on earlier recognition of decompensated cirrhosis, broader access to specialist care, stronger transplant referral pathways, resilient albumin and vasoconstrictor supply, and regionally appropriate reimbursement models. Organizations that combine clinical rigor, market access discipline, pharmacovigilance, and responsible digital innovation will be best positioned to improve outcomes for patients with HRS while building sustainable leadership in advanced liver disease care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hepatorenal Syndrome Treatment Market, by Product Type

• 7.1. Branded
• 7.2. Generic

8. Hepatorenal Syndrome Treatment Market, by Route Of Administration

• 8.1. Intravenous
• 8.2. Oral

9. Hepatorenal Syndrome Treatment Market, by Patient Severity

• 9.1. Type I
• 9.2. Type II

10. Hepatorenal Syndrome Treatment Market, by Treatment Modality

• 10.1. Pharmacotherapy
• 10.2. Renal Replacement Therapy
• 10.3. Transjugular Intrahepatic Portosystemic Shunt
• 10.4. Liver Transplantation

11. Hepatorenal Syndrome Treatment Market, by Drug Class

• 11.1. Vasopressin Analogs
• 11.2. Catecholamines
• 11.3. Alpha-Adrenergic Agonists
• 11.4. Somatostatin Analogs
• 11.5. Plasma Expanders

12. Hepatorenal Syndrome Treatment Market, by End User

• 12.1. Home Care Settings
• 12.2. Hospitals
• 12.3. Specialty Clinics

13. Hepatorenal Syndrome Treatment Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Hepatorenal Syndrome Treatment Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Hepatorenal Syndrome Treatment Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Aetna Inc.
• 17.2. Baxter International Inc
• 17.3. Becton, Dickinson and Company
• 17.4. Biocon Limited
• 17.5. BioVie Inc
• 17.6. Cadila Healthcare Limited
• 17.7. Cumberland Pharmaceuticals Inc
• 17.8. Edwards Lifesciences Corporation
• 17.9. F. Hoffmann-La Roche AG
• 17.10. GlaxoSmithKline plc
• 17.11. Mallinckrodt Inc
• 17.12. Medtronic plc
• 17.13. Neovii Pharmaceuticals AG
• 17.14. Novartis International AG
• 17.15. Orphan Therapeutics, LLC
• 17.16. PharmaIN Corporation
• 17.17. Samarth Life Sciences Pvt Ltd.
• 17.18. Swastik Life Sciences
• 17.19. United Biotech Pvt Ltd.